The EANO Youngsters Initiative aims to provide a platform for networking, interaction and collaboration between young scientists/clinicians with a special interest in Neuro-Oncology. Several activities like the EANO Youngsters Track during the annual Meeting, the Networking Event and our Facebook Group specially focusing on young EANO members were already initiated by the current EANO Youngsters Committee. Importantly, the EANO Youngsters committee aims to represent the diversity of EANO with a lot of different specialties involved in Neuro-Oncology as well as to represent the different scientific interest from a clinical as well as a translational and basic science viewpoint.
To further broaden the projects of the EANO Youngsters Committee we are looking for new motivated members with new ideas for projects, initiatives and actions to improve networking, interactions and collaborations between young scientists with a special interest in Neuro-Oncology. EANO Youngsters Committee does not focus on scientific projects, but aims to increase the involvement of young members in the EANO society.
If you have an idea for the EANO Youngsters Committee, you are under 35 years old and want to join the EANO Youngster Committee send your proposal along with a short motivation letter and CV to email@example.com.
Call for the EANO Youngsters Committee at a glance
- Young EANO Members (age < 35 years)
- Project idea (max 1 page)
- Motivation letter (max ½ page)
Send to firstname.lastname@example.org between 01.04 and 01.06.2020
Applications will be reviewed by the current EANO Youngster Committee and new members will be invited based on the project idea, regional/gender/professional background diversity.
After all, any initiative is living off its participants. So let’s take this opportunity and connect during the EANO Youngster Networking Event or in the EANO Youngsters facebook group.
We are looking forward to fill this initiative with a lot of activities!
Together we aim to address the issues of young Neuro-Oncology scientists within the EANO and provide a platform for interaction as well as organize dedicated activates. Any ideas for new activities? Do not hesitate to contact us via the Facebook group or email: email@example.com
According to the EANO Youngsters
The EANO Youngsters selected the most important scientific neuro-oncology papers of 2019. Instead of just looking at the number of citations or impact factors, we performed a survey in our EANO Youngsters Facebook group. We received a lot of input! We now have an interesting impression of which studies our followers were most interested in this year.
This year's list features important basic science papers, published in high-impact journals, and possible practice-changing clinical papers.
So, here are our top 6 paper:
- Suva group's single cell paper: Neftel C. et al. (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. https://www.ncbi.nlm.nih.gov/pubmed/31327527
- The Nature-trio on synaptic interactions between glioma cells and neurons: Barrier A. Dangerous liaisons as tumour cells form synapses with neurons. Nature (2019) 573, 499-501, doi: 10.1038/d41586-019-02746-7 https://www.nature.com/articles/d41586-019-02746-7
- Taylor group's snRNA paper: Suzuki H. et al. . Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma. Nature. (2019). doi: 10.1038/s41586-019-1650-0. https://www.ncbi.nlm.nih.gov/pubmed/31597162
- Exciting work from the Glioma Longitudinal Analysis (GLASS) Consortium: Barthel, F.P., Johnson, K.C., Varn, F.S. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature (2019) doi:10.1038/s41586-019-1775-1 https://www.nature.com/articles/s41586-019-1775-1
- Whole brain radiotherapy with or without hippocampal avoidance in brain metastases: Tomé W. et al. RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM), Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Pages i23–i24, doi.org/10.1093/noajnl/vdz014.104 https://academic.oup.com/noa/article/1/Supplement_1/i23/5546283
- Lomustine-temozolomide or standard temozolomide therapy in glioblastoma: Herrlinger U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet (2019) 393 (10172), P678-688, doi.org/10.1016/S0140-6736(18)31791-4 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31791-4/fulltext?dgcid=raven_jbs_etoc_email
Advances in Neuro-Oncology : how to translate into clinic
The EANO Winter School aims to provide an update on the recent advances in the pathogenesis and management of CNS tumors with particular attention devoted to the application in the clinical practice. The educational event will include lectures and case-based workshops, and is aimed to attract scientists, physicians and healthcare professionals involved in diagnosis and treatment of brain tumors.
click here for detailed information
The EANO Youngsters facebook group should help to interact with other youngsters more early. Exchange experience and information, ask for advise from the community and share interesting information e.g. on trials or papers. Not yet connected? Just enter “EANO Youngsters” and join the community!